Cargando…

Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort

PURPOSE: The transcription factors YY1 and CP2 have been associated with tumor promotion and suppression in various cancers. Recently, simultaneous expression of both markers was correlated with negative prognosis in cancer. The aim of this study was to explore the expression of YY1 and CP2 in head...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnoell, Julia, Jank, Bernhard J., Kadletz-Wanke, Lorenz, Stoiber, Stefan, Spielvogel, Clemens P., Gurnhofer, Elisabeth, Kenner, Lukas, Heiduschka, Gregor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872999/
https://www.ncbi.nlm.nih.gov/pubmed/33315124
http://dx.doi.org/10.1007/s00432-020-03482-6
_version_ 1783649300590362624
author Schnoell, Julia
Jank, Bernhard J.
Kadletz-Wanke, Lorenz
Stoiber, Stefan
Spielvogel, Clemens P.
Gurnhofer, Elisabeth
Kenner, Lukas
Heiduschka, Gregor
author_facet Schnoell, Julia
Jank, Bernhard J.
Kadletz-Wanke, Lorenz
Stoiber, Stefan
Spielvogel, Clemens P.
Gurnhofer, Elisabeth
Kenner, Lukas
Heiduschka, Gregor
author_sort Schnoell, Julia
collection PubMed
description PURPOSE: The transcription factors YY1 and CP2 have been associated with tumor promotion and suppression in various cancers. Recently, simultaneous expression of both markers was correlated with negative prognosis in cancer. The aim of this study was to explore the expression of YY1 and CP2 in head and neck squamous cell carcinoma (HNSCC) patients and their association with survival. METHODS: First, we analyzed mRNA expression and copy number variations (CNVs) of YY1 and CP2 using “The Cancer Genome Atlas” (TCGA) with 510 HNSCC patients. Secondly, protein expression was investigated via immunohistochemistry in 102 patients, who were treated in the Vienna General Hospital, utilizing a tissue microarray. RESULTS: The median follow-up was 2.9 years (1.8–4.6) for the TCGA cohort and 10.3 years (6.5–12.8) for the inhouse tissue micro-array (TMA) cohort. The median overall survival of the TCGA cohort was decreased for patients with a high YY1 mRNA expression (4.0 vs. 5.7 years, p = 0.030, corr. p = 0.180) and high YY1-CNV (3.53 vs. 5.4 years, p = 0.0355, corr. p = 0.213). Furthermore, patients with a combined high expression of YY1 and CP2 mRNA showed a worse survival (3.5 vs. 5.4 years, p = 0.003, corr. p = 0.018). The mortality rate of patients with co-expression of YY1 and CP2 mRNA was twice as high compared to patients with low expression of one or both (HR 1.99, 95% CI 1.11–3.58, p = 0.021). Protein expression of nuclear YY1 and CP2 showed no association with disease outcome in our inhouse cohort. CONCLUSION: Our data indicate that simultaneous expression of YY1 and CP2 mRNA is associated with shorter overall survival. Thus, combined high mRNA expression might be a suitable prognostic marker for risk stratification in HNSCC patients. However, since we could not validate this finding at genomic or protein level, we hypothesize that unknown underlying mechanisms which regulate mRNA transcription of YY1 and CP2 are the actual culprits leading to a worse survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-020-03482-6.
format Online
Article
Text
id pubmed-7872999
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78729992021-02-22 Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort Schnoell, Julia Jank, Bernhard J. Kadletz-Wanke, Lorenz Stoiber, Stefan Spielvogel, Clemens P. Gurnhofer, Elisabeth Kenner, Lukas Heiduschka, Gregor J Cancer Res Clin Oncol Original Article – Cancer Research PURPOSE: The transcription factors YY1 and CP2 have been associated with tumor promotion and suppression in various cancers. Recently, simultaneous expression of both markers was correlated with negative prognosis in cancer. The aim of this study was to explore the expression of YY1 and CP2 in head and neck squamous cell carcinoma (HNSCC) patients and their association with survival. METHODS: First, we analyzed mRNA expression and copy number variations (CNVs) of YY1 and CP2 using “The Cancer Genome Atlas” (TCGA) with 510 HNSCC patients. Secondly, protein expression was investigated via immunohistochemistry in 102 patients, who were treated in the Vienna General Hospital, utilizing a tissue microarray. RESULTS: The median follow-up was 2.9 years (1.8–4.6) for the TCGA cohort and 10.3 years (6.5–12.8) for the inhouse tissue micro-array (TMA) cohort. The median overall survival of the TCGA cohort was decreased for patients with a high YY1 mRNA expression (4.0 vs. 5.7 years, p = 0.030, corr. p = 0.180) and high YY1-CNV (3.53 vs. 5.4 years, p = 0.0355, corr. p = 0.213). Furthermore, patients with a combined high expression of YY1 and CP2 mRNA showed a worse survival (3.5 vs. 5.4 years, p = 0.003, corr. p = 0.018). The mortality rate of patients with co-expression of YY1 and CP2 mRNA was twice as high compared to patients with low expression of one or both (HR 1.99, 95% CI 1.11–3.58, p = 0.021). Protein expression of nuclear YY1 and CP2 showed no association with disease outcome in our inhouse cohort. CONCLUSION: Our data indicate that simultaneous expression of YY1 and CP2 mRNA is associated with shorter overall survival. Thus, combined high mRNA expression might be a suitable prognostic marker for risk stratification in HNSCC patients. However, since we could not validate this finding at genomic or protein level, we hypothesize that unknown underlying mechanisms which regulate mRNA transcription of YY1 and CP2 are the actual culprits leading to a worse survival. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-020-03482-6. Springer Berlin Heidelberg 2020-12-14 2021 /pmc/articles/PMC7872999/ /pubmed/33315124 http://dx.doi.org/10.1007/s00432-020-03482-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article – Cancer Research
Schnoell, Julia
Jank, Bernhard J.
Kadletz-Wanke, Lorenz
Stoiber, Stefan
Spielvogel, Clemens P.
Gurnhofer, Elisabeth
Kenner, Lukas
Heiduschka, Gregor
Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
title Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
title_full Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
title_fullStr Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
title_full_unstemmed Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
title_short Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
title_sort transcription factors cp2 and yy1 as prognostic markers in head and neck squamous cell carcinoma: analysis of the cancer genome atlas and a second independent cohort
topic Original Article – Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872999/
https://www.ncbi.nlm.nih.gov/pubmed/33315124
http://dx.doi.org/10.1007/s00432-020-03482-6
work_keys_str_mv AT schnoelljulia transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT jankbernhardj transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT kadletzwankelorenz transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT stoiberstefan transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT spielvogelclemensp transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT gurnhoferelisabeth transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT kennerlukas transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort
AT heiduschkagregor transcriptionfactorscp2andyy1asprognosticmarkersinheadandnecksquamouscellcarcinomaanalysisofthecancergenomeatlasandasecondindependentcohort